Gene · 279
AMY2A: amylase alpha 2A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. AMY2A: amylase alpha 2A. Genes, record 279. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/279
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P04746 | Pancreatic alpha-amylase | 511 | 51 | Ensembl, GeneID, HGNC |
Source UniProt
Patents77
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026094314 A | 2026-06-09 | 47 | P04746 | Espacenet |
| JP 2026021360 A | 2026-02-10 | 138 | P04746 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37270 | P04746 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12858 | P04746 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 14353 | P04746 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 785 | P04746 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 786 | P04746 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5470 | P04746 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5470 | P04746 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 14353 | P04746 | Espacenet |
1 to 10 of 77
See all 77 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| ACARBOSE | CHEMBL404271 | Pancreatic alpha-amylase inhibitor | INHIBITOR |
Source ChEMBL
Trials57
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07122102 | ACARBOSE | ClinicalTrials.gov | ||
| NCT07074379 | ACARBOSE | ClinicalTrials.gov | ||
| NCT06993428 | ACARBOSE | PHASE2 | ClinicalTrials.gov | |
| NCT05934110 | ACARBOSE | PHASE2 | ClinicalTrials.gov | |
| NCT05629806 | ACARBOSE | PHASE3 | ClinicalTrials.gov | |
| NCT05487859 | ACARBOSE | PHASE2 | ClinicalTrials.gov | |
| NCT05261997 | ACARBOSE | ClinicalTrials.gov | ||
| NCT05035849 | ACARBOSE | ClinicalTrials.gov | ||
| NCT04665570 | ACARBOSE | ClinicalTrials.gov | ||
| NCT04521751 | ACARBOSE | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsNIH grants291
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AMY2A papers | Newest fiscal year |
|---|---|---|---|
| R35GM133600 | Repetitive sequences drive genome variation and plasticity | 3 | 2025 |
| U24HG007497 | Identifying and Characterizing the Full Spectrum of Haplotype-resolved Structural Variation in Human Genomes | 3 | 2025 |
| P20GM139769 | COBRE in Human Genetics | 2 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 2 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 2 | 2025 |
| P30CA177558 | University of Kentucky Markey Cancer Center – Cancer Center Support Grant | 2 | 2025 |
| R00GM147352 | Human centromere variation and function | 2 | 2025 |
| R01CA237159 | Mechanisms of pancreatic cancer initiation and progression from normal human pancreatic tissue | 2 | 2025 |
| R01CA261934 | Mobile element mutagenesis as a driver of human cancers | 2 | 2025 |
| R01HG002385 | Long-read sequence and assembly of segmental duplications | 2 | 2025 |
1 to 10 of 291Source NIH's project files
See all 291 nih grantsPapers797
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Unfolding the Pharmacological Potentialities and Phytochemical Characterization of Pajanelia longifolia (Wild) Leaves: A Multidimensional Study via GC-MS/MS, In Vitro, In Vivo, and In Silico Approaches. | Chem Biodivers | 2026 | 42571622 | PubTator, text mining | PubMed |
| Design, synthesis, and biological evaluation of a dichloro-substituted schiff base as an α-amylase inhibitor: structural, computational, and molecular dynamics, in-silico approaches. | J Biomol Struct Dyn | 2026 | 42543020 | PubTator, text mining | PubMed |
| Flavonoid C-glycosides in Fabaceae seeds: From structural diversity and functional significance to human health benefits. | Food Chem | 2026 | 42442107 | PubTator, text mining | PubMed |
| Antidiabetic activity of Cassia javanica flowers through in vitro inhibitory evaluation of α-amylase, α-glucosidase and its antiglycation property. | Nat Prod Res | 2026 | 42430509 | PubTator, text mining | PubMed |
| Novel β-defensin-like marine miniprotein magnificamide-2 with a remarkable potency in inhibiting mammalian α-amylases. | Int J Biol Macromol | 2026 | 42419540 | PubTator, text mining | PubMed |
| Design, synthesis, and biological evaluation of p-thymol-derived 1,2,4-triazole sulfonyl hydrazides as potent α-amylase and α-glucosidase inhiabitors: molecular docking and ADME insights. | In Silico Pharmacol | 2026 | 42389728 | PubTator, text mining | PubMed |
| Coumarin-based small molecules for diabetes management: rational design, computational studies, synthesis, and biological evaluation. | J Comput Aided Mol Des | 2026 | 42350715 | PubTator, text mining | PubMed |
| Design, synthesis, biological evaluation, and in silico characterization of chalcone derivatives as antidiabetic hits. | Sci Rep | 2026 | 42342702 | PubTator, text mining | PubMed |
In vitro alpha amylase and protein denaturation inhibitory activity of newer generation Schiff base Oxazolone derivatives: Synthesis, chemical characterization, molecular docking, MD simulation, DFT, ADMET, and bioactivity. | Biochem Biophys Res Commun | 2026 | 42330886 | PubTator, text mining | PubMed |
| Convergent evolution through independent rearrangements in the primate amylase locus. | Cell Rep | 2026 | 42184164 | PubTator, text mining | PubMed |
1 to 10 of 797
See all 797 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/279
GET https://conductscience.org/api/genes/v1/279/patents?page=2